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Abstract: Primary tumor targeting is the dominant approach in drug development, while metastasis
is the leading cause of cancer death. Therefore, in addition to the cytotoxic activity of a series of
Ru(II) polypyridyl complexes of the type [Ru(dip)2L]2+ (dip: 4,7-diphenyl-1,10-phenanthroline
while L = dip; bpy: 2,2′-bipyridine; bpy-SC: bipyridine derivative bearing a semicarbazone 2-
formylopyridine moiety; dpq, dpq(CH3)2, dpb: quinoxaline derivatives) their ability to inhibit
cell detachment was investigated. In vitro studies performed on lung cancer A549 cells showed that
they accumulate in cells very well and exhibit moderate cytotoxicity with IC50 ranging from 4 to
13 µM. Three of the studied compounds that have dip, bpy-SC, or dpb ligands after treatment of the
cells with a non-toxic dose (<1/2IC50) enhanced their adhesion properties demonstrated by lower
detachment in the trypsin resistance assay. The same complexes inhibited both MMP-2 and MMP-9
enzyme activities with IC50 ranging from 2 to 12 µM; however, the MMP-9 inhibition was stronger.
More detailed studies for [Ru(dip)2(bpy-SC)]2+, which induced the greatest increase in cell adhesion,
revealed that it is predominately accumulated in the cytoskeletal fraction of A549 cells. Moreover,
cells treated with this compound showed the localization of MMP-9 to a greater extent also in the
cytoskeleton. Taken together, our results indicate the possibility of a reduction of metastatic cells
escaping from the primary lesion to the surrounding tissue by prevention of their detachment and by
influencing the activity of MMP-2 and MMP-9.
Keywords: ruthenium(II) polypyridyl complexes; matrix metalloproteinases; inhibition of MMP-2
and MMP-9; cell adhesion properties; cytotoxicity; cell detachment; cellular uptake
1. Introduction
Cancer is a group of diseases associated with abnormal cells that grow out of control
with the potential to invade other parts of the organism. The uncontrolled cell growth may
lead to the formation of tissue mass called primary tumor [1]. The process by which cancer
cells degrade surrounding tissues, overcome biological barriers, colonize, and proliferate
in a distant part of the organism to form a secondary tumor is called metastasis. In
numerous types of cancer, metastasis is the most dangerous attribute of diseases, which is
responsible for poor prognosis, complications, and high mortality [2–4]. Despite increasing
understanding of the risks associated with the formation and development of metastasis,
still, there are no efficient antimetastatic therapies. Therefore, design agents that would not
only target the primary tumor but also inhibit metastasis are of great importance.
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Metastasis is a very complex process involving several steps [5,6] that begins with
the detachment of neoplastic cells from the primary tumor. Extracellular matrix (ECM), a
three-dimensional non-cellular component present within all tissues that provides struc-
tural and biochemical support to surrounding cells, can be regarded as a major obstacle in
the first stage of metastasis. It constitutes a physical barrier and basement for cells, and its
composition ensures proper ECM-cell and cell–cell interaction and adhesion. Matrix metal-
loproteinases (MMPs) are enzymes capable of degrading and remodeling ECM [7,8]. They
play an important role in cancer cell survival and expansion as they are involved in all stages
of carcinogenesis [9]. By degradation of various adhesion molecules, they can modulate
cell–cell and cell–ECM adhesion. For metastasis progression matrix metalloproteinases-2
and -9 (MMP-2 and MMP-9) are crucial since they regulate migration and epithelial to mes-
enchymal transition. The proteolytic activity of these enzymes results in the degradation
of physical barriers enabling cancer cell invasion. In addition, they are involved in tumor
angiogenesis and vasculogenesis. Considering such a diverse role of MMP-2 and MMP-9,
targeting these enzymes seems to be a good strategy to achieve antimetastatic activity.
Ruthenium polypyridyl complexes have been tested for many years for their use in
anticancer therapy as cytotoxic agents [10–12]. Recently, ours and other studies have shown
that ruthenium polypyridyl compounds in addition to their well-documented cytotoxic
activity can affect various cell properties such as detachment, motility, invasion, coloniza-
tion ability, and others that are crucial for metastasis formation and development [13–19].
The detailed mechanism of such activity is still largely unknown; however, some of these
compounds have been shown to strongly alter cell adhesion properties. MMP-2 and
MMP-9 were considered among the postulated targets, and it was shown that some of
the ruthenium polypyridyl complexes may inhibit their activity [19], while others may
down-regulate their secretion [14,16]. In this study, for the first time, we investigate the
relationship between the localization of Ru in the cell and the expression level of MMPs by
analyzing subcellular fractions, which may strengthen the hypothesis of MMPs as potential
targets for Ru polypyridyl complexes.
In this work, a series of Ru(II) polypyridyl complexes of the type [Ru(dip)2L]2+
(L = bpy, bpy-SC, dip, dpb, dpq, or dpq(CH3)2; depicted in Figure 1) was investigated to
gain insight into their effect on cell adhesion properties as well as their potency in matrix
metalloproteinases inhibition. The impact of the studied compounds on human lung
adenocarcinoma A549 cells viability and their susceptibility to detachment was assessed
and related to their uptake and localization. Moreover, their influence on the MMP-2 and
MMP-9 expression in A549 cells and inhibition potency towards these enzymes were evalu-
ated. The trans-[tetrachlorido(1H-imidazole)(S-dimethylsulphoxide)ruthenate(III)] known
as NAMI-A with well-documented antimetastatic properties and the broad-spectrum MMP
inhibitor GM0006 were used as reference compounds. NAMI-A is an unquestionable leader
in research on antimetastatic properties of Ru complexes, and detailed information on its
activity is given in recent reviews [20,21].Pharmaceuticals 2021, 14, 1014 3 of 14  
 
 
Figure 1. The studied ruthenium(II) polypyridyl complexes. 
2. Results and Discussion  
2.1. Cytotoxicity and Uptake 
The viability of human lung adenocarcinoma cells (A549) decreased by treatment 
with all studied Ru(II) polypyridyl complexes in a dose-dependent manner. The cytotox-
icity of the studied compounds ranged from 5 to 12 µM (Figure 2), which makes them 
moderately cytotoxic. However, they are much more cytotoxic than cisplatin, with IC50 of 
70 µM [22]. All studied complexes accumulated in live A549 cells. Quantification of the 
ruthenium ion concentration using ICP-MS revealed that treatment of cells with 1 µM 
concentration of Ru(II) compounds increased their concentration in a cell by 6 to 55-fold, 
depending on compound (Figure 2B). The most cytotoxic compound [Ru(dip)3]2+ was 
characterized by the highest uptake by cells, which correlated well with the highest lipo-
philicity. There is no direct correlation between the lipophilicity, uptake, and cytotoxicity 
for the other tested compounds, suggesting different accumulation profiles and targets, 
which are determined by the structure of the L ligand. Therefore, knowledge of complex 
lipophilicity does not allow for the prediction of the degree of cellular uptake. Further-
more, not only the amount of the accumulated compound is important, but also its local-
ization and activity towards potential targets, most likely different proteins.  
  
Figure 1. The studied ruthenium(II) polypyridyl complexes.
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The study was designed to recognize the role of L ligand in the observed biological ac-
tivity and examine the relationship between hampering of cell detachment and decreasing
activity of MMP-2 and MMP-9 either by reducing their expression or by direct inhibition.
2. Results and Discussion
2.1. Cytotoxicity and Uptake
The viability of human lung adenocarcinoma cells (A549) decreased by treatment with
all studied Ru(II) polypyridyl complexes in a dose-dependent manner. The cytotoxicity of
the studied compounds ranged from 5 to 12 µM (Figure 2), which makes them moderately
cytotoxic. However, they are much more cytotoxic than cisplatin, with IC50 of 70 µM [22].
All studied complexes accumulated in live A549 cells. Quantification of the ruthenium
ion concentration using ICP-MS revealed that treatment of cells with 1 µM concentration
of Ru(II) compounds increased their concentration in a cell by 6 to 55-fold, depending on
compound (Figure 2B). The most cytotoxic compound [Ru(dip)3]2+ was characterized by
the highest uptake by cells, which correlated well with the highest lipophilicity. There is no
direct correlation between the lipophilicity, uptake, and cytotoxicity for the other tested
compounds, suggesting different accumulation profiles and targets, which are determined
by the structure of the L ligand. Therefore, knowledge of complex lipophilicity does not
allow for the prediction of the degree of cellular uptake. Furthermore, not only the amount
of the accumulated compound is important, but also its localization and activity towards
potential targets, most likely different proteins.
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Figure 2. (A) Cytotoxicity (IC50) of the studied Ru(II) complexes evaluated for A549 cells along with 
the calculated lipophilicity (clogP) of the ligand L in complexes of the type [Ru(dip)2L]2+ with the 
use of ChemDraw Professional 17.1. (B) The total amount of the accumulated ruthenium ions in 
A549 cells was determined after 24 h incubation with 1 µM of Ru(II) complexes presented as a con-
centration in single cells. 
2.2. Effect on Adherence Properties of Cells  
Change in cell adherence upon treatment with Ru(II) polypyridyl complexes was 
evaluated as the percentage of the remaining adherent cells upon controlled trypsin treat-
ment compared to control. As shown in Figure 3, the highest increase in cell adherence 
even up to 400% vs. control was observed for Ru complex with bpy-SC ligand. This com-
plex has already been described as a very efficient agent also in reducing the detachment 
of human pancreatic cancer cells [19]. The other three complexes with bpy, dip, or dpb 
ligands also significantly enhanced the adhesive properties of A549 cells, while those with 
dpq and dpq(CH3)2 ligand had a marginal effect on cells adhesion. The observed effect 
was not concentration-dependent and already detected for as low concentration of com-
pounds as 1 µM, which is far away from IC50 for all studied compounds. Considering the 
lipophilicity of ligand L and the cytotoxicity of the Ru complexes, any direct correlation 
can be found that points to the structure of the L ligand as a critical factor affecting the 
adhesion properties of cells. Treatment of A549 cells with NAMI-A resulted also in a sig-
nificant increase of the adhesion strength of cells, up to ca. 250% compared to control but 
it was observed at a much higher concentration of 100 µM (still non-toxic). A similar effect 
of NAMI-A was already reported for B16F10 melanoma cells which treatment with 100 
µM of compound resulted in a significant increase of the adhesion strength, even up to 
162% vs control [23]. In contrast, upon treatment of cells with GM6001, a broad-spectrum 
metalloproteinase inhibitor, in a concentration range 1–8 µM (non-toxic concentration) no 
alteration in cell adhesion properties was observed. 
  
Figure 2. (A) Cytotoxicity (IC50) of the studied Ru(II) complexes evaluated for A549 cells along with the calculated
lipophilicity (clogP) of the ligand L in complexes of the type [Ru(dip)2L]2+ with the use of ChemDraw Professional 17.1.
(B) The total amount of the accumulated ruthenium ions in A549 cells was determined after 24 h incubation with 1 µM of
Ru(II) complexes presented as a concentration in single cells.
2.2. Effect on Adherence Properties of Cells
Change in cell adherence upon treatment with Ru(II) polypyridyl complexes was eval-
uated as the percentage of the remaining adherent cells upon controlled trypsin treatment
compared to control. As shown in Figure 3, the highest increase in cell adherence even up
to 400% vs. control was observed for Ru complex with bpy-SC ligand. This complex has
already been described as a very efficient agent also in reducing the detachment of human
pancreatic cancer cells [19]. The other three complexes with bpy, dip, or dpb ligands also
significantly enhanced the adhesive properties of A549 cells, while those with dpq and
dpq(CH3)2 ligand h d a marginal effect on cells adhesion. The observed effect was not
concentration-dependent and already detected for as low concentration of compounds as
1 µM, which is far away from IC50 for all studied compounds. Considering the lipophilicity
of ligand L and the cytotoxicity of the Ru complexes, any direct correlation can be found
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that points to the structure of the L ligand as a critical factor affecting the adhesion proper-
ties of cells. Treatment of A549 cells with NAMI-A resulted also in a significant increase of
the adhesion strength of cells, up to ca. 250% compared to control but it was observed at
a much higher concentration of 100 µM (still non-toxic). A similar effect of NAMI-A was
already reported for B16F10 melanoma cells which treatment with 100 µM of compound
resulted in a significant increase of the adhesion strength, even up to 162% vs. control [23].
In contrast, upon treatment of cells with GM6001, a broad-spectrum metalloproteinase
inhibitor, in a concentration range 1–8 µM (non-toxic concentration) no alteration in cell
adhesion properties was observed.




































Figure 3. A549 cell adherence, evaluated as the percentage of remaining adherent cells upon con-
trolled trypsin treatment compared to control after incubation with the studied Ru(II) complexes. 
for 24 h. Untreated cells were used as a control (100%). * p < 0.05. 
The localization of the accumulated Ru(II) polypyridyl complexes in the cell depends 
largely on their ligands and occurs in various organelles, the cytoplasm, or it can be dis-
persed throughout the cell [12]. Our previous studies revealed that Ru compounds con-
taining two dip ligands localized primarily in mitochondria and the endoplasmic reticu-
lum [22,24] while [Ru(dip)3]2+ was shown to be mainly localized in the lysosome and the 
mitochondria [25]. To determine whether the localization of the studied Ru(II) 
polypyridyl complexes could be correlated with their effect on cell resistance to trypsin, 
the accumulation of Ru in different cellular compartments was measured for complexes 
weakly ([Ru(dip)2(dpq)]2+) or strongly ([Ru(dip)2(bpy-SC)]2+) increasing cell adherence. As 
shown in Figure 4 ruthenium ions were present in each cellular fraction. For both com-
pounds, a large amount of ruthenium ions was observed in the nuclear fraction. However, 
[Ru(dip)2(bpy-SC)]2+ accumulated to a much greater extent in the cytoskeleton fraction, 
while [Ru(dip)2(dpq)]2+ was primarily localized in membrane extract (Figure 4). Thus, Ru 
complex localized in the cytoskeleton fraction of the cell may be account for the observed 
effect on cell adhesion properties. The focal adhesion is a structural unit that is responsible 
for cell adhesion to the substrate, in our experiment to the plastic surface of the cell culture 
plate. There are many proteins associated with focal adhesion among which integrins play 
a crucial role in regulating cell/substrate interaction. Integrins are attached to the actin 
microfilament components of the cytoskeleton through linker proteins [26]. The ruthe-
nium complex present in the cytoskeleton fraction may interfere with the signaling mech-
anism between integrins and the cytoskeleton assembly, leading to a positive response 
that increases cell adhesion to the substrate. Further studies are needed to support this 
hypothesis.  
Figure 3. A549 cell adherence, evaluated as the percentage of remaining adherent cells upon con-
trolled trypsin treatment compared to control after incubation with the studied Ru(II) complexes. for
24 h. Untreated cells were used as a control (100%). * p < 0.05.
The localization of the accumulated Ru(II) polypyridyl complexes in the cell depends
largely on their ligands and occurs in various organelles, the cytoplasm, or it can be
dispersed throughout the cell [12]. Our previous studies revealed that Ru compounds
containing two dip ligands localized primarily in mitochondria and the endoplasmic
reticulum [22,24] while [Ru(dip)3]2+ was shown to be mainly localized in the lysosome
and the mitochondria [25]. To determine whether the localization of the studied Ru(II)
polypyridyl complexes could be correlated with their effect on cell resistance to trypsin,
the accumulation of Ru in different cellular compartments was measured for complexes
weakly ([Ru(dip)2(dpq)]2+) or strongly ([Ru(dip)2(bpy-SC)]2+) increasing cell adherence.
As shown in Figure 4 ruthenium ions were present in each cellular fraction. For both
compounds, a large amount of ruthenium ions was observed in the nuclear fraction.
However, [Ru(dip)2(bpy-SC)]2+ accumulated to a much greater extent in the cytoskeleton
fraction, while [Ru(dip)2(dpq)]2+ was primarily localized in membrane extract (Figure 4).
Thus, Ru complex localized in the cytoskeleton fraction of the cell may be account for
the observed effect on cell adhesion properties. The focal adhesion is a structural unit
that is responsible for cell adhesion t the substrate, in o r experiment to the plastic
surface of the cell culture plate. There are many proteins associated with focal adhesion
among which integrins play a crucial role in regulating cell/substrate interaction. Integrins
are attached to the actin microfilament components of the cytoskeleton through li ker
proteins [26]. The ruthenium complex present in the cytoskeleton fraction may interfere
with the signaling mechanism between integrins and the cytoskeleton assembly, leading to
a positive response that increases cell dhesion to the substrate. Further studies are needed
to support this hypothesis.
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Figure 4. Ruthenium accumulation profile in different cell compartments after incubating A549 cells 
for 24 h with 4 µM of [Ru(dip)2(bpy-SC)]2+ or [Ru(dip)2(dpq)]2+. * p < 0.05. 
2.3. MMP-2 and MMP-9 Inhibition  
MMP-2 and MMP-9 are two key enzymes involved in ECM-degradation processes. 
It was reported that both enzymes are expressed in A549 cells [27,28]. In this study, the 
expression of MMP-2 and MMP-9 in Ru-treated cells was assessed by Western blot tech-
nique. We were not able to measure MMP-2 activity in A549 cells, as the bands were not 
detectable. However, for MMP-9 antibody, as shown in Figures 5B and S1, there was a 
band of high intensity attributed to the active form of the enzyme (approx. 70 kDa). The 
analysis of intensities of the band attributed to MMP-9 revealed that treatment of A549 
cells with [Ru(dip)2(bpy-SC)]2+ reduced its expression by approx. 36 and 67% after treat-
ment with 1 and 4 µM concentrations, respectively (Figure 5A). The effect of the remaining 
complexes was not so pronounced and although some of them decreased the expression 
of MMP-9 (e.g., complexes with bpy or dip ligands), it was not concentration-dependent. 
A pronounced effect (reduction by 43%) was measured for NAMI-A after treating the cells 
with a concentration of 100 µM. The in vivo studies have demonstrated that NAMI-A is 
able to reduce both MMP-9 pro-enzyme and its active form while MMP-2 reduction was 
less pronounced [23]. Changing the expression levels of MMP-9 is one of, but not the only, 
mechanisms of biological changes manifested by a decrease in cell detachment ability in-
duced in cells by the investigated Ru(II) polypirydyl complexes. 
Figure 4. Ruthenium a cumulation profile in di ferent cell co part e ts after inc bati 5 cells
for 24 h ith 4 µ of [ ( i )2(bpy-SC)]2+ or [Ru(dip)2(dpq)]2+. * p < 0 05.
2.3. MMP-2 and MMP-9 Inhibition
MMP-2 and MMP-9 are two key enzymes involved in ECM-degradation processes.
It was reported that both enzymes are expressed in A549 cells [27,28]. In this study,
the expression of MMP-2 and MMP-9 in Ru-treated cells was assessed by Western blot
technique. We were not able to measure MMP-2 activity in A549 cells, as the bands were not
detectable. However, for MMP-9 antibody, as shown in Figure 5B and Figure S1, there was
a band of high intensity attributed to the active form of the enzyme (approx. 70 kDa). The
analysis of intensities of the band attributed to MMP-9 revealed that treatment of A549 cells
with [Ru(dip)2(bpy-SC)]2+ reduced its expression by approx. 36 and 67% after treatment
with 1 and 4 µM concentrations, respectively (Figure 5A). The effect of the remaining
complexes was not so pronounced and although some of them decreased the expression of
MMP-9 (e.g., complexes with bpy or dip ligands), it was not concentration-dependent. A
pronounced effect (reduction by 43%) was measured for NAMI-A after treating the cells
with a concentration of 100 µM. The in vivo studies have demonstrated that NAMI-A is
able to reduce both MMP-9 pro-enzyme and its active form while MMP-2 reduction was
less pronounced [23]. Changing the expression levels of MMP-9 is one of, but not the
only, mechanisms of biological changes manifested by a decrease in cell detachment ability
induced in cells by the investigated Ru(II) polypirydyl complexes.
In addition, a qualitative evaluation of intracellular localization of MMPs in the
prepared subcellular fractions of Ru-treated cells was performed using Western blot. The
study was carried out for two complexes: [Ru(dip)2(bpy-SC)]2+, which showed high
potency in inhibiting cell detachment, and for [Ru(dip)2(dpq)]2+, which displayed a rather
weak effect on cell detachment. MMP-2 was not detectable in the prepared extracts, while
the presence of MMP-9 was evident. MMP-9 was present to some extent in all the analyzed
fractions of Ru-treated cells as shown in Figure 6. Recently, intracellular MMP-9 has been
shown to be localized primarily in cytosolic/membrane (70%) and to a significantly lower
extent in nuclear compartments (30%) of megakaryocytes cells [29] that is consistent with
our observations. For [Ru(dip)2(bpy-SC)]2+ treated cells higher amount of MMP-9 was
observed in the cytoskeletal fraction of A549 cells, while for [Ru(dip)2(dpq)]2+ membrane
fraction was pivotal localization of MMP-9. This suggests that MMP-9 may be one of the
molecular targets for [Ru(dip)2(bpy-SC)]2+, responsible for its influence on the adhesion
properties of A549 cells.

















































Figure 5. (A) The expression levels of the active form of MMP-9 and (B) Representative image of 
Western blot detection of MMP-9 activity measured in A549 cells after 24 h incubation with 1 or 4 
µM of Ru complexes or GM6001, and 100 µM of NAMI-A. β-actin was used for normalization. * p < 
0.05. 
In addition, a qualitative evaluation of intracellular localization of MMPs in the pre-
pared subcellular fractions of Ru-treated cells was performed using Western blot. The 
study was carried out for two complexes: [Ru(dip)2(bpy-SC)]2+, which showed high po-
tency in inhibiting cell detachment, and for [Ru(dip)2(dpq)]2+, which displayed a rather 
weak effect on cell detachment. MMP-2 was not detectable in the prepared extracts, while 
the presence of MMP-9 was evident. MMP-9 was present to some extent in all the analyzed 
fractions of Ru-treated cells as shown in Figure 6. Recently, intracellular MMP-9 has been 
shown to be localized primarily in cytosolic/membrane (70%) and to a significantly lower 
extent in nuclear compartments (30%) of megakaryocytes cells [29] that is consistent with 
our observations. For [Ru(dip)2(bpy-SC)]2+ treated cells higher amount of MMP-9 was ob-
served in the cytoskeletal fraction of A549 cells, while for [Ru(dip)2(dpq)]2+ membrane 
fraction was pivotal localization of MMP-9. This suggests that MMP-9 may be one of the 
molecular targets for [Ru(dip)2(bpy-SC)]2+, responsible for its influence on the adhesion 
properties of A549 cells. 
Figure 5. (A) The expression levels of the active form of MMP-9 and (B) Representative image of
Western blot detection of MMP-9 activity measured in A549 cells after 24 h incubation with 1 or 4 µM
of Ru complexes or GM6001, and 100 µM of NAMI-A. β-actin was used for normalization. * p < 0.05.
The observed colocalization of the expressed MMP-9 and the tested Ru(II) complexes
suggests that reported biological activity of Ru complexes may originate, among others,
from the inhibition of MMPs activity within the cells. To confirm this, the inhibitory proper-
ties of all studied Ru(II) polypyridyl complexes were determined for MMP-9 and addition-
ally for MMP-2 using the fluorogenic substrate FS-6. As shown in Table 1, two complexes,
namely [Ru(dip)3]2+ and [Ru(dip)2(bpy-SC)]2+, were quite potent in inhibiting both MMP-2
and MMP-9 with IC50 of a few micromolar. Most of the studied complexes were better
inhibitors against MMP-2 than the reference inhibitor GM6001 except for the complexes
containing dpq or dpq(CH3)2 ligand which did not influence MMPs activity at the studied
concentration range. The inhibition of MMP-9 was almost twice as strong as that of MMP-2
for all complexes exhibiting inhibitory activity. NAMI-A showed no inhibitory properties
in the studied range of concentration, up to 600 µM.
Interestingly, the strength of inhibition of both MMP-2 and MMP-9 by the studied
Ru(II) polypyridyl complexes correlates well with their impact on cell adhesion. Such
correlation can be used for further optimizing the structure of ligands in Ru(II) polypyridyl
complexes to obtain compounds that will have even higher influence on cell adhesion
properties. The compound [Ru(dip)2(bpy-SC)]2+ appears to be of great interest as a poten-
tial antimetastatic agent. Its preferential accumulation in a cellular cytoskeleton fraction,
in which increased expression of MMP-9 was assessed, may point to matrix metallopro-
teinases as one of the possible targets. It must be noted that GM6001 although it is a good
inhibitor of MMPs, in particularly MMP-9, it did not affect the adhesion properties of
cells in the trypsin resistance assay. Moreover, NAMI-A which increased the fraction of
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adherent cells in trypsin resistant assay did not affect MMPs activity. Therefore, protease
inhibition is an important feature of ruthenium(II) polypyridyl complexes, in particular
for [Ru(dip)2(bpy-SC)]2+; however other molecular targets need to be identified to better
understand its effect on cell adhesion.























































































Figure 6. (A) MMP-9 localization profile in different cell compartments after incubating A549 cells 
for 24 h with 4 µM of [Ru(dip)2(bpy-SC)]2+ or [Ru(dip)2(dpq)]2+. * p < 0.05. (B) Representative images 
of Western blot detection of MMP-9 activity in different cell compartments after incubating A549 
cells for 24 h with 4 µM Ru complexes. The following notification for extracts was used: CEB—
cytoplasmic, MEB—membrane, NEB1—soluble nuclear, NEB2—chromatin bound nuclear, PEB—
cytoskeletal. 
The observed colocalization of the expressed MMP-9 and the tested Ru(II) complexes 
suggests that reported biological activity of Ru complexes may originate, among others, 
from the inhibition of MMPs activity within the cells. To confirm this, the inhibitory prop-
erties of all studied Ru(II) polypyridyl complexes were determined for MMP-9 and addi-
tionally for MMP-2 using the fluorogenic substrate FS-6. As shown in Table 1, two com-
plexes, namely [Ru(dip)3]2+ and [Ru(dip)2(bpy-SC)]2+, were quite potent in inhibiting both 
MMP-2 and MMP-9 with IC50 of a few micromolar. Most of the studied complexes were 
better inhibitors against MMP-2 than the reference inhibitor GM6001 except for the com-
plexes containing dpq or dpq(CH3)2 ligand which did not influence MMPs activity at the 
studied concentration range. The inhibition of MMP-9 was almost twice as strong as that 
of MMP-2 for all complexes exhibiting inhibitory activity. NAMI-A showed no inhibitory 
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Figure 6. (A) MMP-9 localization profile in different cell compartments after incubating A549 cells for
24 h with 4 µM of [Ru(dip)2(bpy-SC)]2+ or [Ru(dip)2(dpq)]2+. * p < 0.05. (B) Representative images of
Western blot detection of MMP-9 activity in different cell compartments after incubating A549 cells for
24 h with 4 µM Ru complexes. The following notification for extracts was used: CEB—cytoplasmic,
MEB—membrane, NEB1—soluble nuclear, NEB2—chromatin bound nuclear, PEB—cytoskeletal.
Table 1. IC50 values for inhibition of MMP-2 and MMP-9 by studied compounds as well as the
reference metalloproteinase inhibitor GM6001 and antimetastatic agent NAMI-A. Experimental
conditions: [FS-6] = 2.5 µM, [enzyme] = 0.5 nM, 0.1 M Tris, pH 7.4 at 37 ◦C (MMP-2 and MMP-9 were
activated using 1 mM APMA at 4 ◦C overnight, and the buffer was supplemented with 0.1 M NaCl,
10 mM CaCl2, 0.1 mM ZnCl2 and 0.05% Brij35).
Compound IC50 for MMP-2 [µM] IC50 for MMP-9 [µM]
[Ru(dip)2(dpq)]2+ n.i. n.i.
[Ru(dip)2(dpq(CH3)2]2+ n.i. 16.8 ± 9.4
[Ru(dip)2(bpy)]2+ 22.5 ± 2.0 6.2 ± 2.8
[Ru(dip)3]2+ 8.3 ± 1.1 4.1 ± 1.6
[Ru(dip)2(dpb)]2+ 13.1 ± 4.6 9.0 ± 3.7
[Ru(dip)2(bpy-SC)]2+ 8.0 ± 1.1 5.9 ± 1.0
GM6001 34 1 0.6 1
NAMI-A n.i. n.i.
1 data taken from reference [19]. n.i.—no inhibition in the studied ranged (>> 25 µM, for NAMI-A >> 600 µM).
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3. Materials and Methods
3.1. Materials
All solvents were of at least analytical grade and were used without further purifi-
cation. Unless otherwise stated, reagents were purchased from Sigma-Aldrich (St. Luis,
MO, USA). All aqueous solutions were prepared with deionized MiliQ-class water from
Millipore (Burlington, MA, USA) system. The following complexes [Ru(dip)2(bpy)]Cl2,
[Ru(dip)2(bpy-SC)]Cl2, [Ru(dip)3]Cl2 and NAMI-A were prepared according to the pub-
lished procedures [13,24]. The detailed synthesis of [Ru(dip)2(dpb)]Cl2, [Ru(dip)2(dpq)]Cl2
and [Ru(dip)2(dpq(CH3)2)]Cl2 is described in the submitted manuscript [30]. The stock
solutions of Ru(II) polypyridyl complexes were prepared in DMSO while aqueous solution
of NAMI-A was freshly prepared before each experiment and kept on ice no longer than
30 min. Lipophilicity (clogP) of all used ligands was calculated with the use of ChemDraw
Professional 17.1 (Perkin Elmer, Waltham, MA, USA).
3.2. Cell Culture and Cytotoxicity Assay
In vitro studies were conducted using human lung adenocarcinoma A549 cell line.
Cells were routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM, Corning,
Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS, Eurx, Gdańsk, Poland)
(v/v) and 1% penicillin-streptomycin (100 units/mL–100µg/mL, Corning) (v/v) and in-
cubated at 37 ◦C in humidified atmosphere with 5% CO2 (v/v). The cytotoxicity of the
Ru(II) complexes was evaluated using MTT assay (Sigma-Aldrich). Cells were seeded into
96-well plate with the density of 3× 104 cells per cm2 in complete medium and cultured for
24 h. Then medium was removed and various concentrations of the studied compounds
in basic medium were added. The final DMSO concentration in cell culture was fixed
at 0.1% (v/v). After 24 h of incubation with Ru(II) complexes in the concentration range
0–32 µM, cells were washed with medium and 100 µL of MTT solution (0.5 mg/mL) was
added for 3 h. NAMI-A was evaluated up to 200 µM concentration. After the incubation,
MTT was removed, and the formed violet formazan crystals were dissolved in the 100 µL
of DMSO:methanol (1:1) mixture. The absorbance was measured using Tecan Infinite
200 microplate reader (Tecan, Männedorf, Switzerland) at 565 nm with 700 nm as a refer-
ence wavelength. Experiments were performed in triplicates and repeated three times. IC50
parameters were determined using Hill equation (OriginPro 2020, OriginLab Corporation,
Northampton, MA, USA) and are presented as mean values and the standard deviation of
the mean.
3.3. Cellular Uptake
For cellular uptake A549 cells were seeded in a 6-well plate with the density of
4 × 104 cells per cm2 in complete medium and cultured for 24 h. Then the medium was
removed, and cells were treated with 1 µM (non-toxic concentration) of all studied Ru(II)
complexes in a basic medium for 24 h. Any dead cells were eliminated by washing
cells’ monolayer with PBS. Subsequently, the incubated cells were washed, detached by
trypsin treatment and counted. The cells were isolated by centrifugation and digested in
concentrated nitric acid overnight at room temperature. The solutions were diluted with
Millipore water to a final nitric acid concentration of 2%. The Ru content in the samples
was measured by inductively coupled plasma mass spectrometry (ICP-MS) using NexION
2000C (Perkin Elmer). Experiments were repeated three times. Results were calculated as
ruthenium concentration per cell and presented as mean values and standard deviation of
mean. Similarly, the content of Ru ions was measured in subcellular fraction obtained as
described in chapter 4.5.
3.4. Trypsin Resistance Assay
Cells susceptibility to detachment upon incubation with the studied compounds was
evaluated by checking their resistance to trypsin treatment. Cells were seeded into 96-well
plate with the density of 3 × 104 cells per cm2 in complete medium and cultured for 24 h.
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Then, cells were incubated with various concentrations of the studied compounds for 24 h.
Subsequently, the cells were washed and 30 µL trypsin solution (0.05%) was added to each
well for 10 min incubation at 37 ◦C. Next, cells were washed with PBS and Alamar Blue
assay was performed to quantify adherent cells. The received results were normalized
with appropriate wells without the trypsin treatment to exclude the possible toxicity of the
studied compounds and presented as a percentage of control (untreated) cells. Experiments
were performed in triplicates and each experiment was repeated five times to obtain mean
values and standard error of the mean.
3.5. Subcellular Fractionation
Subcellular fractionation was performed using the subcellular protein fractionation
kit for cultured cells (Thermo Fisher Scientific, Waltham, MA, USA) according to the manu-
facturer’s instructions. Briefly, A549 cells were seeded in a 25 cm2 flask with the density of
1.25 × 106 cells per flask in complete medium and cultured for 24 h. Then, the medium
was removed, and cells were treated with 4 µM (non-toxic concentration) of [Ru(dip)2(bpy-
SC)]Cl2 or [Ru(dip)2(dpq)]Cl2 in a basic medium for 24 h. After the incubation cells were
washed with PBS, detached by trypsin treatment, and counted. A total of 2 mln cells were
collected for fractionation in 1.5 mL microcentrifuge tubes. The following fractions were ob-
tained: CEB—cytoplasmic, MEB—membrane, NEB1—soluble nuclear, NEB2—chromatin
bound nuclear, PEB—cytoskeletal. The prepared extracts were digested in a concentrated
nitric acid overnight at 60 ◦C and later analyzed by inductively coupled plasma mass
spectrometry (ICP-MS) using NexION 2000C (Perkin Elmer). Experiments were repeated
three times. Results were calculated as percentage of ruthenium concentration per cell
and presented as mean values and standard deviation of mean. Additional samples were
prepared and used for quantitative analysis of MMP-2/9 using Western blot as described
in chapter 4.6.
3.6. Western Blot Analysis
A549 cells were seeded in a 25 cm2 flask with the density of 1.25 × 106 cells per
flask in complete medium and cultured for 24 h. Then the medium was removed, and
cells were treated with 1 or 4 µM (non-toxic concentration) of Ru complexes in a basic
medium for 24 h. After the incubation, cells were washed with ice-cold PBS and lysed using
RIPA buffer containing Halt proteases inhibitor cocktail (Thermo Fisher Scientific). Protein
samples (the same concentration per lane) were separated on a 12% sodium dodecyl sulfate
polyacrylamide gel. PageRuler™ Prestained Protein Ladder (Thermo Fisher Scientific) was
used to determine approximate molecular weights of resolved proteins. Electrophoresis
was performed through the stacking gel for 25 min at 60 V and resolving gel for 50 min at
170 V at room temperature using a PowerPac™ Basic Power Supply (Bio-Rad, Inc., Hercules,
CA, USA). A wet electrotransfer was carried out for 2 h at a constant current of 200 mA to
transfer the separated proteins to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad,
Inc., Hercules, CA, USA), followed by blocking in 5% skim milk in TBST over 1 h (Tris-
buffered Saline Tween-20). Furthermore, the membrane was probed with primary antibody
overnight at 4 ◦C: mouse monoclonal anti-MMP-2 antibody (dilution 1:200; Thermo Fisher
Scientific, catalog number MA5-13590); rabbit polyclonal anti-MMP-9 antibody (dilution
1:2000; Thermo Fisher Scientific, catalog number PA5-13199) or mouse monoclonal anti-β-
actin antibody (dilution 1:1000; Thermo Fisher Scientific, catalog number AM4302). After
being washed three times in TBST membrane was incubated with polyclonal secondary
antibody conjugated with horseradish peroxidase for 2 h in room temperature: goat anti-
mouse antibody (dilution 1:10,000; Thermo Fisher Scientific, catalog number G21040) for
MMP-2/β-actin detection or goat anti-rabbit antibody (dilution 1:10,000; Thermo Fisher
Scientific, catalog number G21234) for MMP-9 detection. Reactive protein was detected
after membrane was washed three times in TBST using GE Healthcare Amersham™ ECL
Prime Western Blotting Detection Reagent (GE Healthcare Inc., Chicago, IL, USA). Only
one protein was detected at a time, each membrane was stripped in 0.2 M NaOH over
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20 min, washed three times in water and blocked again before proceeding with another
primary antibody. Data were collected by ChemiDoc XRS+ Imaging System (Bio-Rad, Inc.,
Hercules, CA, USA) and analyzed with Image Lab v. 6.1.0 software (Bio-Rad, Inc., Hercules,
CA, USA). β-actin was used for normalization. Active form of MMP-9 was identified at
70 kDa.
3.7. MMP-2 and MMP-9 Inhibition
Pro-enzymes (MMP-2 and MMP-9), fluorogenic substrate FS-6 (Mca-Lys-Pro-Leu-Gly-
Leu-Dpa-Ala-Arg-NH2) and reference inhibitor for MMPs GM6001 were obtained from
Sigma-Aldrich. MMP-9 and MMP-2 were activated at 4 ◦C using 1 mM APMA overnight
before the experiments. MMP-2 and MMP-9 assays were performed in 0.1 M Tris/HCl
(pH 7.4, 37 ◦C) enriched with 0.1 M NaCl, 10 mM CaCl2, 0.1 mM ZnCl2 and 0.05% Brij35.
The final concentrations of the enzyme and substrate (FS-6) were kept constant at 0.4 nM
and 2.5 µM, respectively. Kinetic fluorescence measurements were performed using a
Perkin Elmer LS55 spectrofluorimeter (λex/λem = 325/400 nm). The obtained fluorescence
intensities were corrected due to inner filter effect according to the following equation [31]:
Fcorr = Fobs·10Aλem+Aλex
where Fobs denotes the measured fluorescence intensity, while Aλem and Aλex are the
absorbance of sample at emission and excitation wavelengths.
The enzyme activity in the presence of inhibitors was expressed as a fraction of initial
reaction rate (vi/v0 ratio, v0—initial reaction rate, vi—initial reaction rate in the presence of
inhibitor). IC50 parameters were calculated from a dose-response plot of enzyme fractional
activity as a function of inhibitor concentration, using the Hill equation (OriginPro2018).
Experiments were repeated three times and results are presented as mean values and
standard deviation of the mean.
To confirm that the changes in fluorescence of FS-6 are solely attributed to the en-
zymatic activity of the MMPs and are not interfered by the possible quenching effect of
Ru(II) polypyridyl compounds, the formation of the fluorescent product resulting from the
cleavage of FS-6 was followed by HPLC. Reaction between MMP-9 and FS-6 was carried
out under the same buffered conditions as for the spectrofluorimetric measurement. After
1, 2, 3, 4, and 5 min 100 µL of the reaction mixture was taken and diluted 10 times with
GM6001 solution, a commercially available MMP inhibitor with an IC50 of 0.6 µM (the final
concentration of GM6001 was 8 µM) for blocking MMP-9 activity. Samples were placed on
ice and separated by HPLC as soon as possible. The chromatograms were registered using
a Perkin Elmer HPLC Chromera system equipped with fluorescence detector (λext 325 nm,
λem 400 nm). Separation was obtained on Brownlee Bio C18 150 × 4.6 mm column, with
ammonia acetate (0.1 M, pH 4.6) and acetonitrile as solvents applied for gradient elution
from 5 to 40% of acetonitrile for 20 min with a flow rate of 1 mL/min. The inhibition activity
was determined for [Ru(dip)2(bpy-SC)]2+ applying the following concentrations: 0; 0.25;
1.25; 7.5; 12.5; 25 µM. The concentrations of MMP-9 and FS-6 were constant, 0.4 nM and
2.5 µM, respectively. Reaction between MMP-9 and FS-6 was carried out in the presence of
each concentration of Ru complex and the progress of the reaction was monitored by the
observation of the peak from the formed fluorescent product. The initial velocities were
calculated from the peak areas and used for calculation of IC50 applying Hill model. IC50
determined for [Ru(dip)2(bpy-SC)]2+ from HPLC method was 4.8 ± 0.7 µM while from
fluorescence assay 5.9 ± 1.0 µM. The spectrofluorimetric method is far more accurate than
HPLC since it directly measures the signal without delay necessary in HPLC separation
as well as stopping enzyme activity prior separation. Nevertheless, the obtained results
point out that spectrofluorimetric assay can be successfully used for determination IC50 for
Ru(II) polypyridyl complexes.
3.8. Statistical Analysis
Data are expressed as the mean ± standard error of the mean (SEM). Significant differ-
ences among tested samples were determined by one way analysis of variance (ANOVA)
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using Statistica 13 software. Probabilities of p < 0.05 were considered to be statistically
significant. The following notification is used * p < 0.05.
4. Conclusions
Inhibiting metastasis at the very beginning is essential for successful anticancer ther-
apy. Cell detachment from the primary tumor followed by invasion is considered the early
phase of metastasis [32]. Among the studies series of Ru(II) polypyridyl complexes three
of them namely [Ru(dip)2(bpy-SC)]2+, [Ru(dip)2(dpb)]2+ and [Ru(dip)3]2+ demonstrated
high activity in inhibiting of cell detachment along with quite efficient inhibition of MMP-2
and MMP-9. More detailed studies for [Ru(dip)2(bpy-SC)]2+ showed its preferential accu-
mulation in the cytoskeleton, where also intracellular MMP-9 was localized to a greater
extent, pointing to this enzyme as one of the targets for this compound. Since GM6001,
an excellent MMP-9 inhibitor, did not induce the enhancement of cell adhesion, it can
be assumed that other targets, most likely localized in the cytoskeleton, are involved in
the biological activity of these compounds. Current knowledge indicates that only those
compounds that can act simultaneously on several targets in the metastatic cascade can
successfully inhibit metastasis [33], therefore the studied compounds are good candidates
for their application as antimetastatic agents.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14101014/s1, Synthetic protocols, Figure S1: Western blot analysis.
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